AIM IMMUNOTECH INC (AIM)

US00901B1052 - Common Stock

0.19  0 (-0.58%)

After market: 0.1962 +0.01 (+3.26%)

Fundamental Rating

1

Taking everything into account, AIM scores 1 out of 10 in our fundamental rating. AIM was compared to 568 industry peers in the Biotechnology industry. AIM has a bad profitability rating. Also its financial health evaluation is rather negative. AIM is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

AIM had negative earnings in the past year.
AIM had a negative operating cash flow in the past year.
AIM had negative earnings in each of the past 5 years.
In the past 5 years AIM always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -176.10%, AIM is not doing good in the industry: 88.14% of the companies in the same industry are doing better.
The Return On Equity of AIM (-821.74%) is worse than 82.83% of its industry peers.
Industry RankSector Rank
ROA -176.1%
ROE -821.74%
ROIC N/A
ROA(3y)-76.87%
ROA(5y)-59.64%
ROE(3y)-122.39%
ROE(5y)-92.13%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 81.05%, AIM belongs to the top of the industry, outperforming 87.08% of the companies in the same industry.
AIM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.05%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

1

2. Health

2.1 Basic Checks

AIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AIM has more shares outstanding
Compared to 5 years ago, AIM has more shares outstanding
There is no outstanding debt for AIM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

AIM has an Altman-Z score of -49.67. This is a bad value and indicates that AIM is not financially healthy and even has some risk of bankruptcy.
AIM's Altman-Z score of -49.67 is on the low side compared to the rest of the industry. AIM is outperformed by 94.16% of its industry peers.
AIM has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.05, AIM is doing worse than 61.42% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -49.67
ROIC/WACCN/A
WACC11.91%

2.3 Liquidity

AIM has a Current Ratio of 0.75. This is a bad value and indicates that AIM is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of AIM (0.75) is worse than 90.97% of its industry peers.
AIM has a Quick Ratio of 0.75. This is a bad value and indicates that AIM is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of AIM (0.75) is worse than 90.97% of its industry peers.
Industry RankSector Rank
Current Ratio 0.75
Quick Ratio 0.75

More info and screens

4

3. Growth

3.1 Past

The earnings per share for AIM have decreased strongly by -12.56% in the last year.
AIM shows a decrease in Revenue. In the last year, the revenue decreased by -1.55%.
AIM shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.26% yearly.
EPS 1Y (TTM)-12.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)-1.55%
Revenue growth 3Y7.41%
Revenue growth 5Y-11.26%
Sales Q2Q%-23.91%

3.2 Future

AIM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.45% yearly.
Based on estimates for the next years, AIM will show a very strong growth in Revenue. The Revenue will grow by 217.99% on average per year.
EPS Next Y43.33%
EPS Next 2Y14.45%
EPS Next 3Y7.26%
EPS Next 5Y12.45%
Revenue Next Year-4.46%
Revenue Next 2Y236.73%
Revenue Next 3Y189.77%
Revenue Next 5Y217.99%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AIM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AIM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.45%
EPS Next 3Y7.26%

More info and screens

0

5. Dividend

5.1 Amount

AIM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AIM IMMUNOTECH INC

NYSEARCA:AIM (12/20/2024, 8:04:00 PM)

After market: 0.1962 +0.01 (+3.26%)

0.19

0 (-0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners13.33%
Inst Owner Change6.16%
Ins Owners8.62%
Ins Owner Change30.1%
Market Cap12.12M
Analysts80
Price Target3.06 (1510.53%)
Short Float %1.07%
Short Ratio1.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.26%
Min EPS beat(2)36.63%
Max EPS beat(2)67.89%
EPS beat(4)2
Avg EPS beat(4)7.4%
Min EPS beat(4)-71.62%
Max EPS beat(4)67.89%
EPS beat(8)5
Avg EPS beat(8)6.16%
EPS beat(12)5
Avg EPS beat(12)-7.26%
EPS beat(16)6
Avg EPS beat(16)-9.26%
Revenue beat(2)2
Avg Revenue beat(2)211.11%
Min Revenue beat(2)98.02%
Max Revenue beat(2)324.21%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.29%
PT rev (3m)-16.28%
EPS NQ rev (1m)-9.09%
EPS NQ rev (3m)-9.09%
EPS NY rev (1m)0%
EPS NY rev (3m)19.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 63.78
P/FCF N/A
P/OCF N/A
P/B 4.16
P/tB 31.89
EV/EBITDA N/A
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS0
BVpS0.05
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -176.1%
ROE -821.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.05%
FCFM N/A
ROA(3y)-76.87%
ROA(5y)-59.64%
ROE(3y)-122.39%
ROE(5y)-92.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 90%
Cap/Sales 113.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.75
Quick Ratio 0.75
Altman-Z -49.67
F-Score2
WACC11.91%
ROIC/WACCN/A
Cap/Depr(3y)144.45%
Cap/Depr(5y)112.12%
Cap/Sales(3y)316.9%
Cap/Sales(5y)315.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y43.33%
EPS Next 2Y14.45%
EPS Next 3Y7.26%
EPS Next 5Y12.45%
Revenue 1Y (TTM)-1.55%
Revenue growth 3Y7.41%
Revenue growth 5Y-11.26%
Sales Q2Q%-23.91%
Revenue Next Year-4.46%
Revenue Next 2Y236.73%
Revenue Next 3Y189.77%
Revenue Next 5Y217.99%
EBIT growth 1Y-18.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-30.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.09%
OCF growth 3YN/A
OCF growth 5YN/A